Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the potential of antiandrogens for androgen-induced baldness in men and women but reports no new clinical findings, emphasizing the need for further research on long-term risks and efficacy.

In this study of a TRPS type I patient, many genes related to keratin and hair development were down-regulated in balding scalp areas, providing new insights into TRPS and hair morphogenesis.

This hypothesis paper proposes that men with X-linked recessive ichthyosis may exhibit no androgenetic alopecia or only mild forms, and suggests clinical studies to evaluate this hypothesis.

This study found differences in urinary androgen and estrogen concentrations between male pattern baldness patients treated with finasteride and healthy controls, suggesting potential biomarkers for post-finasteride syndrome.

In this study, ultraviolet light did not significantly enhance or worsen hair growth induced by topical minoxidil in men with male pattern baldness.

This study found that applying a mix of cholesterol and Tween 60 detergent to mouse skin significantly reduced epidermal cell mitotic activity.

This study found that 32% of men continued finasteride use for 1 to 3 years, with many reporting poor hair growth results.

This study reviewed 26 cases of X-linked recessive ichthyosis and observed 11 patients with advanced-stage androgenetic alopecia, suggesting a compensatory role of two steroid biosynthesis pathways.

This study found that long-term morbidity from scalp skin harvesting for grafts is low, with high patient satisfaction, and androgenetic alopecia is unlikely to uncover underlying harvest-related hair loss.

This review discusses available treatments for androgenetic alopecia in men, like finasteride and 5% minoxidil, and notes that hair growth results are unpredictable and often driven by industry-sponsored studies.

This study suggests obstructive sleep apnea may increase the risk of male-pattern baldness in men with a family history of hair loss, and links low serum transferrin saturation levels to both conditions.

This source notes that topical minoxidil and oral finasteride can modestly maintain or regrow hair in men with androgenic alopecia, especially at the scalp vertex, with minimal side effects.

A trial found that using finasteride, a hair growth drug, can be effectively measured by comparing before and after photos.

This study found that men with androgenetic alopecia at age 20 years may have a higher risk of developing aggressive prostate cancer, particularly advanced stage disease.

This case report details a woman with autoimmune primary ovarian insufficiency linked to hormonal contraception discontinuation, who achieved pregnancy through ovarian stimulation and in vitro fertilization despite typically low fertility in such conditions.

This study found that higher cumulative doses of topical minoxidil solution were strongly associated with improved hair density and thickness in male patients with androgenic alopecia over a 24-week period.

This study found no significant hair growth difference between men treated with polysorbate 60 and those given a placebo, suggesting its ineffectiveness for male pattern baldness.

This review discusses the mechanisms of androgenic alopecia and reports no new results; the development of a mouse model for further study is described.

Keith Kaufman reported promising results on treating male-pattern baldness with oral finasteride at the World Congress of Dermatology.

This study evaluated shaved style scalp medical tattoo (SMT) in individuals with advanced hair loss, reporting high patient and surgeon satisfaction scores.

New drug shows promise for better hair growth in baldness treatment.

This report describes cases of localized alopecia in two girls following hairstyling marketed as the "Princess Package" at a major U.S. theme park, likely due to pressure ischemia and acute traction alopecia, with some regrowth observed but also areas of scarring.

In this study, L-threonate was observed to inhibit DHT-induced DKK-1 expression in dermal papilla cells and reverse DHT's inhibitory effects on outer root sheath cell growth, suggesting potential as a treatment for androgen-driven balding.

This article illustrates the impact of direct-to-consumer drug advertising through a case where a patient sought Rogaine for hair loss without medical assessment, revealing secondary syphilis-related symptoms instead.

This review examines current medical and surgical treatments for androgenetic alopecia, including medications like minoxidil and advancements in hair transplantation techniques, without providing new clinical findings.

This letter discusses concerns about the term "telogen effluvium" and suggests using "telogen defluxion" instead, but reports no new results.

This study found that androgen receptors were more prevalent in bald areas compared to non-bald areas in individuals with androgenic alopecia, suggesting a link between increased local androgen activity and hair loss.

In this study using a macaque model, RU58841 at a 5% concentration significantly increased hair density, thickness, and length in the frontal bald scalp over six months.

This study introduced and evaluated Ahmad's NPRT system for documenting hair loss, finding it helpful in assessing the specific state of male pattern baldness in 500 patients.

This article proposes enhancing the Norwood-Hamilton scale for assessing hair loss patterns but reports no new clinical results.